Press Releases

Date	Title	View
June 11, 2026	Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants	PDF Version
June 11, 2026	Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants	PDF Version
June 11, 2026	Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components	PDF Version
June 3, 2026	Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress	PDF Version
May 21, 2026	Enliven Therapeutics to Present at Upcoming Investor Conferences	PDF Version
May 12, 2026	Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML	PDF Version
May 7, 2026	Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update	PDF Version
March 3, 2026	Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update	PDF Version
February 25, 2026	Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference	PDF Version
January 8, 2026	Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones	PDF Version